High-Value Clinical Pathways Help Illinois Cancer Practice Reduce Drug Spend

Cost savings equate to about $250,000 per medical oncologist over 15 months. 


There's a prevailing belief in oncology that physicians have no power to slow the upward trajectory of drug spend. But New Century Health (NCH) and a community oncology practice explain in a recent journal article how it's possible.        

By marrying NCH's high-value clinical pathways with regular, data-driven discussions about costs and outcomes, Cancer Care Specialists of Illinois (CCSI) reduced its median drug spend by 13.5% as compared to other practices participating in the Oncology Care Model. The cost savings equate to about $3.5 million, or about $250,000 per medical oncologist, over 15 months. Meanwhile, adherence to clinical pathways increased from a baseline of 69% to 81%.

Experts from NCH and CCSI describe their efforts in the May 2020 issue of JCO Oncology Practice:

Learn more about this study:

Previous Article
How Real-World Evidence Can Transform High-Value Oncology Pathways
How Real-World Evidence Can Transform High-Value Oncology Pathways

Our CMO Dr. Andrew Hertler explains how real world evidence may usher in the next generation of clinical on...

Next Article
How Clinical Pathways Are Growing
How Clinical Pathways Are Growing

Increasing use of real-world evidence is one of the most exciting trends in pathway development, our CMO te...